Realtime | Geld | Brief | Zeit |
---|---|---|---|
8,500 | 8,900 | 09.05. |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
29.04. | Elicio Therapeutics, Inc. - 10-K/A, Annual Report | 1 | SEC Filings | ||
05.04. | Elicio Therapeutics, Inc.: Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting | 2 | GlobeNewswire (USA) | ||
05.04. | Elicio Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
29.03. | Elicio Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
29.03. | Elicio Therapeutics, Inc. - 10-K, Annual Report | - | SEC Filings | ||
29.03. | Elicio Therapeutics Inc reports results for the quarter ended in December - Earnings Summary | - | Reuters | ||
29.03. | Elicio Therapeutics GAAP EPS of -$6.96 | 1 | Seeking Alpha | ||
29.03. | Elicio Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
29.03. | Elicio Therapeutics, Inc.: Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates | 316 | GlobeNewswire (Europe) | ELI-002 2P clinical immunogenicity data were accepted for a poster presentation at the AACR Annual Meeting 2024ELI-007 and ELI-008 preclinical data were accepted for a poster presentation at the AACR... ► Artikel lesen | |
18.03. | Elicio Therapeutics to sell 1.03M shares $5.81 in private placement financing | 1 | Seeking Alpha | ||
18.03. | Elicio Therapeutics, Inc.: Elicio Therapeutics Announces $6.0 Million Private Placement Financing | 2 | GlobeNewswire (USA) | ||
18.03. | Elicio Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
06.03. | Elicio Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting | 2 | GlobeNewswire (USA) | ||
21.02. | Elicio's vaccine shows promise as potential cancer treatment in phase 1 trial | 3 | PharmaTimes | ||
05.02. | Elicio Therapeutics Inc.: Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference | 2 | GlobeNewswire (USA) | ||
05.02. | Elicio Therapeutics Announces Publication Of Preclinical Data Demonstrating Power Of Amphiphile-Immunotherapy | 1 | Benzinga.com | ||
02.02. | Elicio Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
31.01. | First Patient Dosed In Phase 2 Study Of Elicio Therapeutics' ELI-002 7P | 1 | Benzinga.com | ||
29.01. | Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutics' AMPLIFY-201 Phase 1 Solid Tumor Study Of ELI-002 | 1 | Benzinga.com | ||
25.01. | Elicio Therapeutics Inc.: Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors | 192 | GlobeNewswire (Europe) | Published data shows lymph node-targeted Amphiphile ("AMP")-peptide and CpG combination with TCR-T cell therapy led to complete eradication and durable responses against established murine solid tumors... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EPIGENOMICS | 1,580 | -3,95 % | EQS-News: Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024 | EQS-News: Epigenomics AG
/ Schlagwort(e): Personalie
Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024
30.04.2024 / 15:00 CET/CEST
Für den Inhalt... ► Artikel lesen | |
NANOREPRO | 1,755 | -3,04 % | Nanorepro braucht neue Ideen | Mitte 2020 stand die Aktie von Nanorepro bei rund einem Euro. Die Corona-Schnelltests der Gesellschaft haben dann Umsatz und Kurs der Aktie nach oben katapultiert. Im März 2021 notierte das Papier bei... ► Artikel lesen | |
OCUGEN | 1,504 | -0,86 % | Ocugen stock is a good speculative buy but there's 1 key risk | ||
SCORPIUS | 0,120 | -2,44 % | Scorpius Holdings, Inc.: Scorpius Holdings Appoints New VP of Business Development Shari Udoff-McDonald | ||
AETERNA ZENTARIS | 7,189 | -2,59 % | XFRA ISIN CHANGE | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenFR0012816825 Biophytis 02.05.2024 FR001400OLP5 Biophytis 03.05.2024 Tausch 400:1US98585K8624 Yield10 Bioscience Inc.... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 1,000 | +3,52 % | Ist es schon so weit? Raus aus KI, Biotech kaufen: Nvidia, Evotec, Defence Therapeutics und Bayer im Fokus | Wieder ein Schlag ins Kontor! Zum Monatsschluss April stürzt die Technologiebörse Nasdaq zum dritten Mal ab und zeigt mit 17.333 Punkten erneut große Schwäche. Nach einem langen Aufwärtstrend des NDX... ► Artikel lesen | |
VIKING THERAPEUTICS | 74,00 | +0,52 % | Viking Therapeutics' Options Frenzy: What You Need to Know | ||
BIOCRYST PHARMACEUTICALS | 4,742 | -3,48 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update | -Q1 2024 ORLADEYO net revenue grows 30 percent y-o-y to $88.9 million- -Full-year 2024 ORLADEYO revenue guidance adjusted to $390-$400 million (top end of prior guidance range) - -Pipeline programs... ► Artikel lesen | |
REDHILL BIOPHARMA | 0,419 | -1,53 % | RedHill Biopharma Ltd.: RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035 | The new Chinese patent for opaganib as a therapy for inhibition of single-stranded RNA virus replication (notably Ebola Disease Virus) is valid through 2035 and adds to opaganib's strong global intellectual... ► Artikel lesen | |
VAXART | 0,653 | -2,90 % | Vaxart, Inc.: Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers | Antibody rise observed in lactating mothers and in their breast milk Long-term goal is to provide protection to infants through passive antibody transfer SOUTH SAN FRANCISCO, Calif., April 30, 2024... ► Artikel lesen | |
IBIO | 1,840 | 0,00 % | Pre-market Movers: iBio, Direct Digital Holdings, Nuvation Bio, PaySign, LuxUrban Hotels | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 07.30 A.M. ET).In the Green iBio, Inc. (IBIO) is up over 86% at $2.14.
Nuvation... ► Artikel lesen | |
ARBUTUS BIOPHARMA | 2,598 | 0,00 % | Arbutus Biopharma Corporation: Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024 | WARMINSTER, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology... ► Artikel lesen | |
ALDEYRA | 3,686 | +0,44 % | Aldeyra Therapeutics, Inc. - 8-K, Current Report | ||
GINKGO BIOWORKS | 0,820 | -6,82 % | GreenLab Partners with Ginkgo Bioworks to Scale Up Production of Brazzein, a Novel Sweetener | Plant Trait Services, Protein Services, and Deployment Capabilities JONESBORO, Ark. and BOSTON, May 7, 2024 /PRNewswire/ -- GreenLab, an emerging next generation plant-biotechnology company producing... ► Artikel lesen | |
MANNKIND | 4,215 | +4,54 % | MannKind Corp. Q1 Earnings Summary | WASHINGTON (dpa-AFX) - Below are the earnings highlights for MannKind Corp. (MNKD):Earnings: $10.63 million in Q1 vs. -$9.80 million in the same period last year.
EPS: $0.04 in Q1 vs. -$0.04... ► Artikel lesen |